Views & Analysis | Perspectives on pharma industry issues

Digital

Building agentic AI in healthcare

Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

R&D

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

Digital

Patient access will not improve without better digital found...

Digital health cannot succeed without infrastructure that supports it at every level.

Sales & Marketing

Company Profile: Viseven

There is no doubt that pharma has developed quite a bit regarding its digital maturity. That said, there is still much room left for growth.

Views & Analysis

Bringing the promise of immunotherapy to a broader populatio...

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a li

Sales & Marketing

Gene therapies for prevalent diseases in Europe – the perfec...

In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gat

Sales & Marketing

Why trust is becoming pharma’s most important visibility met...

Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.

Sales & Marketing

Pharma is marketing to the wrong mind

On the benefits of instinctive marketing, over either rational or emotional.

Digital

Building agentic AI in healthcare

Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Patients